# Vor Biopharma Inc.: financial statements, quarterly

VOR · Nasdaq · CIK 1817229 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vor.md) · [Financials](/companies/vor/financials.md) · [Filings](/companies/vor/filings.md) · [Insiders](/companies/vor/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vor/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [20.9 d](/filings/0000950170-25-042623.md) | [24.3](/filings/0000950170-25-071349.md) | [21.8](/filings/0000950170-25-107276.md) | [21.8](/filings/0001193125-25-280104.md) | [25.3 d](/filings/0001193125-26-130451.md) | [26.7](/filings/0001193125-26-220689.md) | [261](/filings/0001193125-26-343607.md) | [14.1](/filings/0001193125-26-439905.md) | [19.2 d](/filings/0001193125-26-130451.md) | [17.6](/filings/0001193125-26-220689.md) | [25.9](/filings/0001193125-26-343607.md) | [34.5](/filings/0001193125-26-439905.md) |
| Operating income | $m | [(28.1) d](/filings/0000950170-25-042623.md) | [(32.3)](/filings/0000950170-25-071349.md) | [(29.0)](/filings/0000950170-25-107276.md) | [(28.5)](/filings/0001193125-25-280104.md) | [(31.3) d](/filings/0001193125-26-130451.md) | [(33.3)](/filings/0001193125-26-220689.md) | [(274)](/filings/0001193125-26-343607.md) | [(28.1)](/filings/0001193125-26-439905.md) | [(36.0) d](/filings/0001193125-26-130451.md) | [(35.2)](/filings/0001193125-26-220689.md) | [(47.9)](/filings/0001193125-26-343607.md) | [(58.4)](/filings/0001193125-26-439905.md) |
| Net income | $m | [(26.3) d](/filings/0000950170-25-042623.md) | [(30.8)](/filings/0001193125-25-280104.md) | [(27.8)](/filings/0001193125-25-280104.md) | [(27.6)](/filings/0001193125-25-280104.md) | [(30.7) d](/filings/0001193125-26-130451.md) | [(32.5)](/filings/0001193125-26-439905.md) | [(1,574)](/filings/0001193125-26-439905.md) | [(813)](/filings/0001193125-26-439905.md) | [1,723 d](/filings/0001193125-26-130451.md) | [(220)](/filings/0001193125-26-439905.md) | [(62.8)](/filings/0001193125-26-439905.md) | [(86.7)](/filings/0001193125-26-439905.md) |
| Diluted EPS | $ per share | not reported | [(0.45)](/filings/0000950170-25-071349.md) | [(0.41)](/filings/0000950170-25-107276.md) | [(8.05)](/filings/0001193125-25-280104.md) | not reported | [(5.21)](/filings/0001193125-26-220689.md) | [(251.24)](/filings/0001193125-26-343607.md) | [(121.63)](/filings/0001193125-26-439905.md) | not reported | [(5.11)](/filings/0001193125-26-220689.md) | [(1.16)](/filings/0001193125-26-343607.md) | [(1.45)](/filings/0001193125-26-439905.md) |
| Basic EPS | $ per share | not reported | [(0.45)](/filings/0000950170-25-071349.md) | [(0.41)](/filings/0000950170-25-107276.md) | [(8.05)](/filings/0001193125-25-280104.md) | not reported | [(5.21)](/filings/0001193125-26-220689.md) | [(251.24)](/filings/0001193125-26-343607.md) | [(121.63)](/filings/0001193125-26-439905.md) | not reported | [(5.11)](/filings/0001193125-26-220689.md) | [(1.16)](/filings/0001193125-26-343607.md) | [(1.45)](/filings/0001193125-26-439905.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [31.4](/filings/0000950170-25-042623.md) | [45.0](/filings/0000950170-25-071349.md) | [76.1](/filings/0000950170-25-107276.md) | [52.8](/filings/0001193125-25-280104.md) | [81.9](/filings/0001193125-26-130451.md) | [50.0](/filings/0001193125-26-220689.md) | [191](/filings/0001193125-26-343607.md) | [160](/filings/0001193125-26-439905.md) | [396](/filings/0001193125-26-439905.md) | [170](/filings/0001193125-26-220689.md) | [108](/filings/0001193125-26-343607.md) | [79.0](/filings/0001193125-26-439905.md) |
| Current assets | $m | [141](/filings/0000950170-25-042623.md) | [112](/filings/0000950170-24-056846.md) | [90.3](/filings/0000950170-24-093858.md) | [67.3](/filings/0000950170-24-123245.md) | [96.5](/filings/0001193125-26-130451.md) | [64.8](/filings/0000950170-25-071349.md) | [205](/filings/0000950170-25-107276.md) | [172](/filings/0001193125-25-280104.md) | [458](/filings/0001193125-26-439905.md) | [501](/filings/0001193125-26-220689.md) | [475](/filings/0001193125-26-343607.md) | [491](/filings/0001193125-26-439905.md) |
| Total assets | $m | [198](/filings/0000950170-25-042623.md) | [167](/filings/0000950170-24-056846.md) | [142](/filings/0000950170-24-093858.md) | [116](/filings/0000950170-24-123245.md) | [143](/filings/0001193125-26-130451.md) | [109](/filings/0000950170-25-071349.md) | [205](/filings/0000950170-25-107276.md) | [176](/filings/0001193125-25-280104.md) | [464](/filings/0001193125-26-439905.md) | [507](/filings/0001193125-26-220689.md) | [481](/filings/0001193125-26-343607.md) | [496](/filings/0001193125-26-439905.md) |
| Current liabilities | $m | [15.6](/filings/0000950170-25-042623.md) | [13.2](/filings/0000950170-24-056846.md) | [13.8](/filings/0000950170-24-093858.md) | [14.3](/filings/0000950170-24-123245.md) | [18.6](/filings/0001193125-26-130451.md) | [16.7](/filings/0000950170-25-071349.md) | [58.8](/filings/0000950170-25-107276.md) | [18.8](/filings/0001193125-25-280104.md) | [25.2](/filings/0001193125-26-439905.md) | [16.1](/filings/0001193125-26-220689.md) | [24.8](/filings/0001193125-26-343607.md) | [36.3](/filings/0001193125-26-439905.md) |
| Total liabilities | $m | [47.4](/filings/0000950170-25-042623.md) | [44.0](/filings/0000950170-24-056846.md) | [43.5](/filings/0000950170-24-093858.md) | [43.0](/filings/0000950170-24-123245.md) | [46.2](/filings/0001193125-26-130451.md) | [43.2](/filings/0000950170-25-071349.md) | [1,711](/filings/0000950170-25-107276.md) | [2,402](/filings/0001193125-25-280104.md) | [628](/filings/0001193125-26-439905.md) | [657](/filings/0001193125-26-220689.md) | [681](/filings/0001193125-26-343607.md) | [633](/filings/0001193125-26-439905.md) |
| Shareholders' equity | $m | [151](/filings/0001193125-26-130451.md) | [123](/filings/0001193125-25-280104.md) | [98.1](/filings/0001193125-25-280104.md) | [73.0](/filings/0001193125-25-280104.md) | [96.7](/filings/0001193125-26-439905.md) | [66.1](/filings/0001193125-26-439905.md) | [(1,506)](/filings/0001193125-26-439905.md) | [(2,225)](/filings/0001193125-26-439905.md) | [(164)](/filings/0001193125-26-439905.md) | [(150)](/filings/0001193125-26-439905.md) | [(200)](/filings/0001193125-26-439905.md) | [(137)](/filings/0001193125-26-439905.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(24.0) d](/filings/0000950170-25-042623.md) | [(30.5)](/filings/0000950170-25-071349.md) | [(21.8) d](/filings/0000950170-25-107276.md) | [(23.3) d](/filings/0001193125-25-280104.md) | [(24.1) d](/filings/0001193125-26-130451.md) | [(31.1)](/filings/0001193125-26-220689.md) | [(35.2) d](/filings/0001193125-26-343607.md) | [(53.7) d](/filings/0001193125-26-439905.md) | [(22.8) d](/filings/0001193125-26-130451.md) | [(38.2)](/filings/0001193125-26-220689.md) | [(25.4) d](/filings/0001193125-26-343607.md) | [(32.7) d](/filings/0001193125-26-439905.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-25-042623.md) | [0.1](/filings/0000950170-25-071349.md) | [0.0 d](/filings/0000950170-25-107276.md) | [0.0 d](/filings/0001193125-25-280104.md) | [0.1 d](/filings/0001193125-26-130451.md) | [0.2](/filings/0001193125-26-220689.md) | [0.2 d](/filings/0001193125-26-343607.md) | [0.2 d](/filings/0001193125-26-439905.md) | [0.3 d](/filings/0001193125-26-130451.md) | [0.0](/filings/0001193125-26-220689.md) | [0.1 d](/filings/0001193125-26-343607.md) | [0.0 d](/filings/0001193125-26-439905.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [66.3](/filings/0000950170-24-056846.md) | [67.0](/filings/0000950170-24-093858.md) | [67.6](/filings/0000950170-24-123245.md) | [68.0](/filings/0000950170-25-071349.md) | [68.3](/filings/0000950170-25-107276.md) | [3.4](/filings/0001193125-25-280104.md) | [6.2](/filings/0001193125-26-220689.md) | [6.3](/filings/0001193125-26-343607.md) | [6.7](/filings/0001193125-26-439905.md) | [43.0](/filings/0001193125-26-220689.md) | [54.3](/filings/0001193125-26-343607.md) | [59.7](/filings/0001193125-26-439905.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,434,344 at 2026-10-26, from the cover of the [10-Q filed 2026-10-30](/filings/0001193125-26-439905.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 03:06 ET. No prices; not investment advice.